Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 9, 2009

Synexus Expands Operations in South Africa with Two Clinical Trial Research Units

  • Clinical trials company Synexus formally opened two new dedicated research centers in Pretoria, South Africa. They will complement Synexus’ existing site in South Africa, which has a 36-bed Phase I and IIa trial unit.

    U.K.-based Synexus is a multinational company dedicated to the recruitment and running of clinical trials. In October 2008 the company announced plans to double its clinical trials capacity in South Africa and claims that it is on track to reach that goal by the end of 2009.

    Ian Smith, M.D., Synexus’ medical director, states that the company’s operations in South Africa have shown “impressive” growth year-on-year. “The combination of the large patient population and the highly skilled medical community make it a sought after destination for pharmaceutical and biotech companies who are finding patient recruitment increasingly difficult. We currently have four major trials under way here, all part of wider international studies, as well as more than 30 Phase I to Phase III trials.”

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »